Project Grant R21AI202189
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $424K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $2,036,679 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct high-throughput screening and characterization of small-molecule inhibitors targeting N-terminal autoproteolysis of coronavirus main protease precursors. The recipient will develop and execute cell-based assays to identify compounds that selectively interfere with precursor-mediated...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Colorado, doing business as University of Colorado-Denver, $186,953 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize a secreted protease from Corynebacterium that inhibits Staphylococcus aureus virulence. The project grant (R21AI196550) runs through January 31, 2028, with work performed in Aurora, Colorado. The...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Colorado (University of Colorado-Denver) $429,000 under CFDA 93.855 (Allergy and Infectious Diseases Research) on June 8, 2026, to engineer enterococcal bacteriophages as immunomodulatory agents for inflammatory bowel disease. The project will engineer bacteriophages to perform dual functions: deplete pathogenic enterococci from the intestine while simultaneously delivering heterologous...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases awarded $766,730 to the University of Colorado-Denver on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriocins produced by Staphylococcus hominis skin commensals and their protective mechanisms against skin pathogens. The research focuses on identifying and characterizing diverse bacteriocins produced by S. hominis strains isolated from human skin that inhibit pathogenic S....
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $949,073 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop SNAP-TB, a multivalent tuberculosis subunit vaccine candidate for human translation. The funded work, performed in Fort Collins, Colorado, through August 31, 2031, refines a vaccine formulation leveraging the Spontaneous Nanoliposome Antigen Particlization (SNAP) platform to display...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of Colorado $221,875 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish mechanisms by which the AcrAB-TolC resistance-nodulation-division (RND) efflux pump contributes to bacterial virulence in Enterobacteriaceae. The research will determine whether AcrAB-TolC is required for infection to enable physiological responses to nitrosative stress and...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $427,625 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing R21AI200336) to investigate the structure, biosynthesis, and pathogenic role of a previously unknown glycan receptor found on Acinetobacter baumannii and to characterize the molecular interaction between a broad host-range bacteriophage (STAB3) and that receptor. A. baumannii is a...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $192,500 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of enteroendocrine cells in West Nile Virus replication and transmission in Culex tarsalis mosquitoes. The research comprises two aims: Aim 1 will use dissociated midgut cells from colonized mosquitoes infected with barcoded WNV, flow cytometry, and sequencing to quantify the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Denver $159,560 on July 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on metallophore biosynthetic gene clusters and their role in plasmid conjugation, bacterial virulence, and pathogenicity. The research addresses the global emergence of multidrug-resistant bacteria fueled by horizontal transfer of antimicrobial resistance genes between bacteria via...